Proteomics International Laboratories Ltd (ASX:PIQ)

Market Cap	94.12M
Revenue (ttm)	3.31M +1.3%
Net Income	-8.11M
EPS	-0.06
Shares Out	165.12M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,485,228
Average Volume	734,068
Open	0.5500
Previous Close	0.5700
Day's Range	0.4700 - 0.5500
52-Week Range	0.2850 - 0.8600
Beta	-0.14
RSI	41.51
Earnings Date	Feb 23, 2026

About ASX:PIQ

Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia. It provides PromarkerD, a blood test to predict diabetic kidney disease (DKD). The company’s products under development include PromarkerEndo, which has completed clinical validation phase for endometriosis diagnosis; PromarkerEso, which has completed clinical validation trials for esophageal cancer diagnosis; and OxiDx (2-tag), which has comple...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: PIQ

Financial Performance

In fiscal year 2025, ASX:PIQ's revenue was 3.31 million, an increase of 1.34% compared to the previous year's 3.27 million. Losses were -8.11 million, 27.3% more than in 2024.